Literature DB >> 27929373

Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.

Amy W Ku1, Jason B Muhitch1,2, Colin A Powers3, Michael Diehl1, Minhyung Kim3, Daniel T Fisher1,3, Anand P Sharda2, Virginia K Clements4, Kieran O'Loughlin5, Hans Minderman5, Michelle N Messmer1, Jing Ma6, Joseph J Skitzki3, Douglas A Steeber7, Bruce Walcheck6, Suzanne Ostrand-Rosenberg4, Scott I Abrams1, Sharon S Evans1.   

Abstract

Myeloid-derived suppressor cells (MDSC) contribute to an immunosuppressive network that drives cancer escape by disabling T cell adaptive immunity. The prevailing view is that MDSC-mediated immunosuppression is restricted to tissues where MDSC co-mingle with T cells. Here we show that splenic or, unexpectedly, blood-borne MDSC execute far-reaching immune suppression by reducing expression of the L-selectin lymph node (LN) homing receptor on naïve T and B cells. MDSC-induced L-selectin loss occurs through a contact-dependent, post-transcriptional mechanism that is independent of the major L-selectin sheddase, ADAM17, but results in significant elevation of circulating L-selectin in tumor-bearing mice. Even moderate deficits in L-selectin expression disrupt T cell trafficking to distant LN. Furthermore, T cells preconditioned by MDSC have diminished responses to subsequent antigen exposure, which in conjunction with reduced trafficking, severely restricts antigen-driven expansion in widely-dispersed LN. These results establish novel mechanisms for MDSC-mediated immunosuppression that have unanticipated implications for systemic cancer immunity.

Entities:  

Keywords:  L-selectin; T cell trafficking; cancer biology; human; immunology; lymph node; mouse; myeloid-derived suppressor cells

Mesh:

Substances:

Year:  2016        PMID: 27929373      PMCID: PMC5199197          DOI: 10.7554/eLife.17375

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  83 in total

Review 1.  Journey through the thymus: stromal guides for T-cell development and selection.

Authors:  Yousuke Takahama
Journal:  Nat Rev Immunol       Date:  2006-02       Impact factor: 53.106

Review 2.  MDSC in autoimmunity.

Authors:  James G Cripps; James D Gorham
Journal:  Int Immunopharmacol       Date:  2011-02-21       Impact factor: 4.932

3.  ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding.

Authors:  Ying Li; Jennifer Brazzell; Amy Herrera; Bruce Walcheck
Journal:  Blood       Date:  2006-05-30       Impact factor: 22.113

4.  Targeting ADAM17 in leukocytes increases neutrophil recruitment and reduces bacterial spread during polymicrobial sepsis.

Authors:  Hemant K Mishra; Timothy J Johnson; Davis M Seelig; Bruce Walcheck
Journal:  J Leukoc Biol       Date:  2016-04-08       Impact factor: 4.962

5.  Mechanical anchoring strength of L-selectin, beta2 integrins, and CD45 to neutrophil cytoskeleton and membrane.

Authors:  J Y Shao; R M Hochmuth
Journal:  Biophys J       Date:  1999-07       Impact factor: 4.033

6.  ADAM17 cleaves CD16b (FcγRIIIb) in human neutrophils.

Authors:  Yue Wang; Jianming Wu; Robert Newton; Nooshin S Bahaie; Chunmei Long; Bruce Walcheck
Journal:  Biochim Biophys Acta       Date:  2012-12-08

7.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

8.  The characterization of lymphocytes migrating through chronically inflamed tissues.

Authors:  T B Issekutz; W Chin; J B Hay
Journal:  Immunology       Date:  1982-05       Impact factor: 7.397

9.  Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.

Authors:  Chien-Ying Liu; Yu-Min Wang; Chih-Liang Wang; Po-Hao Feng; How-Wen Ko; Yun-Hen Liu; Yi-Cheng Wu; Yen Chu; Fu-Tsai Chung; Chih-Hsi Kuo; Kang-Yun Lee; Shu-Min Lin; Horng-Chyuan Lin; Chun-Hua Wang; Chih-Teng Yu; Han-Pin Kuo
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

10.  Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.

Authors:  Dongshu Chen; Jianchuan Xia; Yasuhiro Tanaka; Hongsong Chen; Shigeo Koido; Oliver Wernet; Pinku Mukherjee; Sandra J Gendler; Donald Kufe; Jianlin Gong
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

View more
  40 in total

Review 1.  Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer.

Authors:  Asha Jayakumar; Alfred L M Bothwell
Journal:  J Immunol       Date:  2019-09-01       Impact factor: 5.422

Review 2.  Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation.

Authors:  Joseph R Scalea; Young Suk Lee; Eduardo Davila; Jonathan S Bromberg
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

3.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

Review 4.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

Authors:  Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

5.  Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.

Authors:  Justin Zonneville; Sean Colligan; Sydney Grant; Alexandra Miller; Paul Wallace; Scott I Abrams; Andrei V Bakin
Journal:  Int J Cancer       Date:  2020-05-28       Impact factor: 7.396

Review 6.  Defining the Hallmarks of Metastasis.

Authors:  Danny R Welch; Douglas R Hurst
Journal:  Cancer Res       Date:  2019-05-03       Impact factor: 12.701

7.  In situ thermal ablation augments antitumor efficacy of adoptive T cell therapy.

Authors:  Fumito Ito; Trupti D Vardam; Michelle M Appenheimer; Kevin H Eng; Sandra O Gollnick; Jason B Muhitch; Sharon S Evans
Journal:  Int J Hyperthermia       Date:  2019-11       Impact factor: 3.914

Review 8.  Myeloid-driven mechanisms as barriers to antitumor CD8+ T cell activity.

Authors:  Sean H Colligan; Stephanie L Tzetzo; Scott I Abrams
Journal:  Mol Immunol       Date:  2019-12-26       Impact factor: 4.407

Review 9.  Developmental pathways of myeloid-derived suppressor cells in neoplasia.

Authors:  Scott I Abrams
Journal:  Cell Immunol       Date:  2020-12-16       Impact factor: 4.868

Review 10.  Selectins in cancer immunity.

Authors:  Lubor Borsig
Journal:  Glycobiology       Date:  2018-09-01       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.